WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H408179
CAS#: 2349336-18-9
Description: This product is removed due to commercial reason
Hodoodo Cat#: H408179
Name: OBX02-011 (removed)
CAS#: 2349336-18-9
Chemical Formula: C29H39ClN8O3S
Exact Mass: 614.26
Molecular Weight: 615.194
Elemental Analysis: C, 56.62; H, 6.39; Cl, 5.76; N, 18.21; O, 7.80; S, 5.21
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: OBX 02-011; OBX-02-011; OBX02-011; OBX 02011; OBX-02011; OBX02011;
IUPAC/Chemical Name: N-[2-[[5-Chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]phenyl]-N-methylmethanesulfonamide
InChi Key: OZRNZXPMNJNRPE-UHFFFAOYSA-N
InChi Code: InChI=1S/C29H39ClN8O3S/c1-35-15-17-38(18-16-35)21-11-13-37(14-12-21)22-9-10-25(27(19-22)41-3)33-29-31-20-23(30)28(34-29)32-24-7-5-6-8-26(24)36(2)42(4,39)40/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)
SMILES Code: CS(=O)(N(C1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3OC)=NC=C2Cl)C)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 615.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer. Cancer Res. 2022 Aug 26:OF1. doi: 10.1158/0008-5472.CAN-22-2507. Epub ahead of print. PMID: 36018295.
2: Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Correction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer. Cancer Res. 2022 Aug 25:OF1. doi: 10.1158/0008-5472.CAN-22-2377. Epub ahead of print. Erratum for: Cancer Res. 2022 Jun 14;: PMID: 36006687.
3: Choi YJ, Kim DS, Hoon Sung Y, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer. Cancer Res. 2022 Jun 14:canres.0394.2022-2-3 21:03:12.200. doi: 10.1158/0008-5472.CAN-22-0394. Epub ahead of print. Retraction in: Cancer Res. 2022 Aug 26;:OF1. Erratum in: Cancer Res. 2022 Aug 25;:OF1. PMID: 35700239.